Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royal Bank of Canada (TSX:RY)

175.84 +1.65 (+0.95%)
Streaming Delayed Price Updated: 4:18 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royal Bank of Canada

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
GoodRx Strengthens Core Business With New Initiatives, Analyst Upgrades On Potential Opportunities
GoodRx has been upgraded by RBC Capital Markets due to the growth potential from the Integrated Savings Program, direct contracting initiatives, and manufacturing solutions expansion. 
Via Benzinga
RBC Stock Earnings: RBC Bearings Beats EPS, Beats Revenue for Q4 2024
RBC stock results show that RBC Bearings beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2024. 
Via InvestorPlace
Gold Gains 1%; RBC Bearings Shares Rise After Q4 Results
Via Benzinga
Why Is RBC Bearings Stock Trading Higher Today?
RBC Bearings reported Q4 results with net sales up 4.9%, gross margin and EBITDA margin expanding. Backlog at $726.1M. Adjusted EPS beat estimates. 
Via Benzinga
Applied Materials, RBC Bearings And 3 Stocks To Watch Heading Into Friday
Via Benzinga
(RBC) - Analyzing RBC Bearings's Short Interest
Via Benzinga
How Is The Market Feeling About RBC Bearings?
Via Benzinga
How Is The Market Feeling About RBC Bearings?
Via Benzinga
RBC Bearings Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
Attention Biotech Investors - Stocks To Watch
RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences,... 
Via Benzinga
RBC Capital Just Raised Its Price Target on Sweetgreen (SG) Stock
Sweetgreen stock is up on Friday after SG shares got positive coverage from RBC Capital analysts alongside Q1 results and steak news. 
Via InvestorPlace
All Canadian Renovations Ltd. Had Celebrity Sponsor At 2024 Winnipeg Renovation Show
Via GetFeatured
InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present at Upcoming RBC Capital Markets Global Healthcare Conference
Via Investor Brand Network
Glencore-Anglo American Tie-Up Makes More Sense Than BHP Offer, Analyst Says
RBC analyst says Glencore and Anglo American make a better match for potential bidding war for Anglo, with potential for higher synergies. 
Via Benzinga
Winnipeg Landscaping Business Participates in Home + Garden Show for Second Year in a Row
Via GetFeatured
1 Wall Street Analyst Thinks Tesla Stock Is Going to $293. Is It a Buy Around $170?
RBC Capital likes Tesla's cost controls and robotaxi development plans. 
Via The Motley Fool
Equinox Gold Completes US$299 Million Bought Deal Financing
Vancouver, British Columbia--(Newsfile Corp. - April 26, 2024) - Equinox Gold Corp. (TSX: EQX) (NYSE American: EQX) (the "Company") is... 
Via Newsfile
Salesforce Leverages AI and Data Cloud for Future Expansion, Eyes Significant Margin Gains and Sustained Growth, Analyst Says
RBC analyst reiterated Outperform rating for Salesforce with raised price target. Customers enthusiastic about generative AI, strong margin growth. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Taylor Morrison: A Home Building Stock You Can Buy at a Discount
Taylor Morrison stock is one homebuilder stock that still has some upside left to it, analysts like the way fundamentals have developed. 
Via MarketBeat
Exposures COVID-19
Norfolk Southern's $600M Agreement To Solve East Palestine Derailment Is A Negative, Says Analyst
RBC analyst Walter Spracklin maintains a Sector Perform rating for Norfolk Southern Corp , setting a $270 price target. Norfolk Southern reported Q1 FY24 revenues of $3.004 billion and an adjusted EPS... 
Via Benzinga
$1000 Invested In RBC Bearings 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Tesla Is Navigating Free FSD Trials, Gigafactory Challenges, and Governance Hurdles: Analyst
RBC analyst maintains Outperform rating on TSLA with $298 price target. Q4 saw demand pull-forward and disruptions in Berlin, FSD free trials expected to drive Q2 volumes. HSBC analyst retains Reduced... 
Via Benzinga
What's Going On With Carvana Stock?
Evercore ISI Group analyst Michael Montani maintained Carvana with an In-Line rating and raised the price target on the stock from $68 to $75 Tuesday. Carvana received two significant analyst upgrades... 
Via Benzinga
InvestorNewsBreaks – Cboe Canada Inc. Announces Three New RBC Bond EFTs Now Listed, Trading
Via Investor Brand Network
Topics Bonds ETFs Economy
Exposures Debt Markets Economy
Analyst Downgrades Berry Global: Is the Center of the Aisle Falling Out?
RBC Capital Markets downgrades BERY to Sector Perform, cuts price target to $62. Analyst cites potential volume and price headwinds in near term. 
Via Benzinga
Tesla Bull Unfazed By Stock Slump On Elon Musk's 'Decades Perspective,' Says This Factor Will Be Next Major Boost
"Elon doesn't think about things on a day-to-day or month-to-month basis; He's looking at things from a years, if not decades, perspective," said RBC Capital Markets analyst Tom Narayan. 
Via Benzinga
What's In Store For Nike In Q3 Earnings? Analyst Sees Revenue Decline In North America & EMEA
RBC Capital Markets analyst maintains Outperform rating on Nike but lowers price forecast to $110 ahead of its Q3 fiscal 2024 earnings release, despite highlighting China momentum and marketing... 
Via Benzinga
RBC Capital Maintains Outperform Rating for Lexeo Therapeutics: Here's What You Need To Know
Via Benzinga
RBC Just Cut Its Price Target on Lucid Motors (LCID) Stock in Half
LCID stock has fallen by about 25% year-to-date to the $3 level. RBC analyst Tom Narayan believes that's where it should trade. 
Via InvestorPlace
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO
REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.